Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 1/20 | 0.46 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.46 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.46 |
| ▸ | MAPKAPK2 | P49137 | 3/20 | 0.43 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | ATR | Q13535 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 2/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.39 |
| ▸ | BCL2 | P10415 | 1/20 | 0.38 |
| ▸ | SYK | P43405 | 1/20 | 0.38 |
| ▸ | FSHR | P23945 | 1/20 | 0.37 |
| ▸ | ABL1 | P00519 | 1/20 | 0.37 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30832555 | 1.00 | GSK3B (0.46) | GSK3BDYRK1ANOTUMMAPKAPK2DGAT1 | |
| SCHEMBL28781893 | 0.84 | GAA (0.46) | GSK3BDYRK1ANOTUMMAPKAPK2DGAT1 | |
| SCHEMBL29008076 | 0.83 | MAPKAPK2 (0.46) | GSK3BDYRK1AMAPKAPK2ATRNAMPT | |
| SCHEMBL21695369 | 0.82 | NOTUM (0.50) | NOTUMMEN1MAPTKMT2ASMN1; SMN2 | |
| SCHEMBL22259406 | 0.82 | GSK3B (0.43) | GSK3BDYRK1AMAPKAPK2MEN1KMT2A | |
| SCHEMBL2666942 | 0.82 | MAPKAPK2 (0.43) | GSK3BDYRK1AMAPKAPK2TSHRATR | |
| SCHEMBL29498375 | 0.82 | GSK3B (0.43) | GSK3BDYRK1AMAPKAPK2MEN1KMT2A | |
| SCHEMBL26947076 | 0.82 | GSK3B (0.43) | GSK3BDYRK1AMAPKAPK2ATRNAMPT | |
| SCHEMBL8815572 | 0.81 | GSK3B (0.42) | GSK3BDYRK1AMAPKAPK2TSHRATR | |
| SCHEMBL32681571 | 0.81 | SIRT6 (0.42) | GSK3BDYRK1AMAPKAPK2MEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102863396-A | Chemical synthesis method for N-Boc-5-aminopyrazine-2-formaldehyde | UNIV NANTONG | 2013-01-09 | — | — | CN | claimed |
| US-11826365-B2 | Type II raf kinase inhibitors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-11826365-B2 | Type II raf kinase inhibitors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-11826365-B2 | Type II raf kinase inhibitors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-20200297721-A1 | TYPE II RAF KINASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-09-24 | — | — | US | disclosed |
| US-20200297721-A1 | TYPE II RAF KINASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-09-24 | — | — | US | disclosed |
| US-10660888-B2 | Aminoheteroaryl benzamides as kinase inhibitors | NOVARTIS AG (CH) | 2020-05-26 | — | — | US | disclosed |
| US-10660888-B2 | Aminoheteroaryl benzamides as kinase inhibitors | NOVARTIS AG (CH) | 2020-05-26 | — | — | US | disclosed |
| EP-2781508-B9 | NITROGEN-CONTAINING FUSED RING COMPOUNDS FOR USE AS CRTH2 ANTAGONISTS | KBP BIOSCIENCES CO LTD (CN) | 2019-08-21 | — | — | EP | disclosed |
| US-20190247392-A1 | AMINOHETEROARYL BENZAMIDES AS KINASE INHIBITORS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2019-08-15 | — | — | US | disclosed |
| US-7709475-B2 | 5-[2-(cyclohexyloxy)-6-methyl-4-pyrimidinyl]-2-[5-(4-methyl-1-piperazinyl)methyl-2-pyrazinyl]amino-1,3-thiazole; anticarcinogenic agent; G1 phase in cell cycle; great selectivity | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-05-04 | — | — | US | disclosed |
| US-20100105683-A1 | COMPOUNDS USEFUL FOR INHIBITING CHK1 | KEEGAN KATHLEEN S | 2010-04-29 | — | — | US | disclosed |
| US-7608618-B2 | Urea or thiourea substituted 1,4-pyrazine compounds useful as anti-cancer agents and for inhibiting Chk1 | ICOS CORPORATION (US) | 2009-10-27 | — | — | US | disclosed |
| US-20080081811-A1 | Selective Inhibitors Against Cdk4 and Cdk6 Having Aminothiazole Skeleton | BANYU PHARMACEUTICAL CO., LTD (JP) | 2008-04-03 | — | — | US | disclosed |
| US-7067506-B2 | Compounds useful for inhibiting Chk1 | ICOS CORPORATION (US) | 2006-06-27 | — | — | US | disclosed |
| US-20050245525-A1 | Compounds useful for inhibiting CHK1 | ICOS CORPORATION (US) | 2005-11-03 | — | — | US | disclosed |
| EP-1379510-A1 | ARYL AND HETEROARYL UREA CHK1 INHIBITORS FOR USE AS RADIOSENSITIZERS AND CHAMOSENSITIZERS | ICOS CORPORATION (US) | 2004-01-14 | — | — | EP | disclosed |
| US-20030069284-A1 | Compounds useful for inhibiting Chk1 | ICOS CORPORATION (A WASHINGTON CORPORATION) | 2003-04-10 | — | — | US | disclosed |
| WO-2002070494-A1 | ARYL AND HETEROARYL UREA CHK1 INHIBITORS FOR USE AS RADIOSENSITIZERS AND CHAMOSENSITIZERS | ICOS CORPORATION (US) | 2002-09-12 | — | — | WO | disclosed |
| WO-2001079262-A1 | PYRAZINONE AND PYRIDINONE DERIVATIVES AS THROMBIN INHIBITORS | CORVAS INTERNATIONAL, INC. (US) | 2001-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190247392-A1 | AMINOHETEROARYL BENZAMIDES AS KINASE INHIBITORS | ABL1, MAP3K12, MAP3K2 | GSK3B 347/4885DYRK1A 440/4885NOTUM 3016/4885 |
| US-20100105683-A1 | COMPOUNDS USEFUL FOR INHIBITING CHK1 | CHEK1, PCNA, CHEK2 | GSK3B 1598/4885DYRK1A 1162/4885NOTUM 3034/4885 |
| US-20050245525-A1 | Compounds useful for inhibiting CHK1 | CHEK1, PCNA, CHEK2 | GSK3B 1598/4885DYRK1A 1162/4885NOTUM 3034/4885 |
| US-20080081811-A1 | Selective Inhibitors Against Cdk4 and Cdk6 Having Aminothiazole Skeleton | CDK4, CDK6, CDK3 | GSK3B 494/4885DYRK1A 357/4885NOTUM 2452/4885 |
| US-10660888-B2 | Aminoheteroaryl benzamides as kinase inhibitors | ABL1, MAP3K12, MAP3K2 | GSK3B 347/4885DYRK1A 440/4885NOTUM 3016/4885 |
| US-11826365-B2 | Type II raf kinase inhibitors | BRAF, RAF1, ARAF | GSK3B 579/4885DYRK1A 544/4885NOTUM 4533/4885 |
| US-20030069284-A1 | Compounds useful for inhibiting Chk1 | CHEK1, PCNA, CHEK2 | GSK3B 1598/4885DYRK1A 1162/4885NOTUM 3034/4885 |
| US-20200297721-A1 | TYPE II RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | GSK3B 579/4885DYRK1A 544/4885NOTUM 4533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.